News
| 2009-04-24 |
Dr. John Dong to present at the 7th Annual Biodefense Vaccines and Therapeutics Conference. |
| July 15-17th, 2009, Almas Temple Club, Washington, DC. Leading Decision Makers Provide a Briefing On the New Administration's Initiatives On Biodefense Vaccines and Therapeutics |
| Industry Panel: Working with DOD This panel of industry representatives will discuss their experience working with the Department of Defense during the development of their biodefense products, the key challenges they faced, and their key success factors. Panelists: John Dong, M.D., Ph.D., President & CSO, GenPhar, Inc. Stan Goldman, Ph.D., Director of Technology, Evolva, Genetic Chemistry Inc. Robert House, MSPH, Ph.D., President, DynPort Vaccine Company LLC, A CSC Company  Conference website |
| About GenPhar, Inc. GenPhar, Inc. is a biopharmaceutical company dedicated to becoming a leader in developing and producing prophylactic and therapeutic vaccines to protect against the world’s most dangerous diseases. To reach its goals, GenPhar will leverage the advantage of its proven safe and effective ProVax and TheraVax vaccine platforms -- unique technology capable of producing multiple vaccine products. GenPhar's products are divided into two main areas: vaccines for biodefense and vaccines for chronic infectious diseases (including HIV, hepatitis B and hepatitis C). These products will have a large scale socio-economic impact and transformative effect on current research and treatments. GenPhar was founded in 1999 and is headquartered in Mount Pleasant, South Carolina. To learn more about GenPhar and its vaccine programs, please contact us. |
print this page
contact us
site map